Fusaric acid, a mycotoxin, and its influence on blood coagulation and platelet function.
The current study intended to explore the effect of fusaric acid on blood coagulation including plasma coagulation and platelet aggregation. Fusaric acid exhibited biphasic effects on citrated human plasma recalcification time. At concentrations below 50 ng, fusaric acid decreased the clotting time of plasma dose-dependently from 130 ± 3s control value to 32 ± 3s; however, above 50 ng, fusaric acid increased the clotting time from 32 ± 3s and reached a maximum of 152 s at 100 ng and remained unaltered thereafter for the increased dose of fusaric acid. Fusaric acid without damaging red blood cells and platelets, inhibited agonists such as collagen, ADP, thrombin, and epinephrine-induced aggregation of both platelet-rich plasma (PRP) and washed platelets preparations of human. Interestingly, fusaric acid showed biphasic effects only in thrombin-induced platelet aggregation of washed platelets, and at lower concentration (below 900 ng) it activated platelet aggregation; however, in increased concentration (above 900 ng) it inhibited the platelet aggregation of washed platelets. In addition, fusaric acid also inhibited the agonist ADP-induced platelet aggregation of washed platelet suspension but did not show biphasic effect. Further, fusaric acid did not induce the platelets to generate reactive oxygen species (ROS) that clearly suggests that the induction of platelet function could be the result of the fusaric acid-mediated receptor interaction but not through the morphological shape change.
Department of Studies and Research in Biochemistry and Center for Bioscience and Innovation, Tumkur University, Tumkur, India.
Sannaningaiah
S
Devaraja
Kesturu S
KS
Girish
Martin S
MS
Santhosh
Mahadevappa
M
Hemshekhar
Siddaiah C
SC
Nayaka
Kempaiah
K
Kemparaju
D000244:Adenosine Diphosphate / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D001792:Blood Platelets / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D048430:Cell Shape / Q000187:drug effects; D002478:Cells, Cultured; D003094:Collagen / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004837:Epinephrine / Q000494:pharmacology; D004912:Erythrocytes / Q000166:cytology / Q000187:drug effects*; D005669:Fusaric Acid / Q000494:pharmacology*; D006801:Humans; D009183:Mycotoxins / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D017382:Reactive Oxygen Species / Q000032:analysis; D013917:Thrombin / Q000494:pharmacology
D009183:Mycotoxins; D017382:Reactive Oxygen Species; D000244:Adenosine Diphosphate; D003094:Collagen; D013917:Thrombin; D005669:Fusaric Acid; D004837:Epinephrine